DOCSLIB.ORG

Addendum to the Toxicological Profile for Formaldehyde

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Addendum to the Toxicological Profile for Formaldehyde ADDENDUM TO THE TOXICOLOGICAL PROFILE FOR FORMALDEHYDE Agency for Toxic Substances and Disease Registry Division of Toxicology and Environmental Medicine Atlanta, GA 30333 October 2010 FORMALDEHYDE ii CONTENTS LIST OF FIGURES ..................................................................................................................................... iv LIST OF TABLES........................................................................................................................................ v Background Statement ................................................................................................................................. vi 2. HEALTH EFFECTS................................................................................................................................ 1 2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....................................................1 2.2.2 Oral Exposure .................................................................................................................................... 58 2.2.3 Dermal Exposure ............................................................................................................................... 64 2.3 TOXICOKINETICS .................................................................................................................................. 66 2.3.3 Metabolism ........................................................................................................................................ 66 2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ..........................66 2.4 MECHANISMS OF ACTION ................................................................................................................... 70 2.4.1 Pharmacokinetic Mechanisms ........................................................................................................... 70 2.4.3 Animal-to-Human Extrapolations ..................................................................................................... 73 2.5 Relevance to Public Health ........................................................................................................................ 74 2.6 CHILDREN’S SUSCEPTIBILITY ............................................................................................................ 75 2.7 BIOMARKERS OF EXPOSURE AND EFFECT .....................................................................................76 2.7.1 Biomarkers Used to Identify or Quantify Exposures to Formaldehyde .............................................76 2.7.2 Biomarkers Used to Characterize Effects Caused by Formaldehyde ................................................78 2.8 INTERACTIONS WITH OTHER CHEMICALS .....................................................................................79 2.10 METHODS FOR REDUCING TOXIC EFFECTS ...................................................................................79 2.10.1 Reducing Peak Absorption Following Exposure ...............................................................................80 2.10.2 Reducing Body Burden ..................................................................................................................... 81 2.11 ADEQUACY OF THE DATABASE ........................................................................................................ 81 2.11.2 Identification of Data Needs .............................................................................................................. 81 2.11.3 Ongoing Studies ................................................................................................................................ 82 3. CHEMICAL AND PHYSICAL INFORMATION ................................................................................ 83 4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL ............................................................ 83 4.1 PRODUCTION .......................................................................................................................................... 83 4.2 IMPORT/EXPORT .................................................................................................................................... 90 4.3 USE ............................................................................................................................................................ 90 4.4 DISPOSAL ................................................................................................................................................. 93 5. POTENTIAL FOR HUMAN EXPOSURE ........................................................................................... 94 5.1 OVERVIEW .............................................................................................................................................. 94 5.2 RELEASES TO THE ENVIRONMENT ................................................................................................... 94 5.2.1 Air ..................................................................................................................................................... 95 5.2.2 Water ............................................................................................................................................... 101 5.2.3 Soil .................................................................................................................................................. 101 5.3 ENVIRONMENTAL FATE .................................................................................................................... 102 5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT ................................................103 5.4.1 Air ................................................................................................................................................... 103 5.4.2 Water ............................................................................................................................................... 105 5.4.4 Other Environmental Media ............................................................................................................ 105 5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE ......................................................106 5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES ............................................................107 5.8.2 Ongoing Studies .............................................................................................................................. 108 6. ANALYTICAL METHODS ............................................................................................................... 111 6.1 BIOLOGICAL MATERIALS .................................................................................................................. 111 6.2 ENVIRONMENTAL SAMPLES ............................................................................................................ 111 FORMALDEHYDE iii 6.3 ADEQUACY OF THE DATABASE ...................................................................................................... 114 6.3.2 Ongoing Studies .............................................................................................................................. 114 7. REGULATIONS, ADVISORIES, AND GUIDELINES ..................................................................... 115 8. REFERENCES .................................................................................................................................... 122 FORMALDEHYDE iv LIST OF FIGURES 2-1. Health Effects of Breathing Formaldehyde ............................................................................ 2 2-2. Health Effects of Ingesting Formaldehyde ............................................................................. 3 FORMALDEHYDE v LIST OF TABLES 2-1. Genotoxicity of Formaldehyde In Vivo ................................................................................ 40 2-2. Genotoxicity of Formaldehyde In Vitro ............................................................................... 44 2-3. Human Case Reports—Ingestion of Formalin ..................................................................... 59 4-1. U.S. Formaldehyde Capacity and Production ...................................................................... 85 4-2. Facilities that Produce, Process, or Use Formaldehyde ........................................................ 87 4-3. Distribution of Formaldehyde Production According to Uses in the United States ............. 92 5-1. Releases to the Environment from Facilities that Produce, Process, or Use Formaldehyde ...................................................................................................................... 96 5-2. The Contribution of Various Atmospheric Environments to the Average Exposure to Formaldehyde .................................................................................................................... 107 5-3. Ongoing Studies on Formaldehyde .................................................................................... 109 6-1. Analytical Methods for Determining Formaldehyde in Biological Materials .................... 111 6-2. Analytical Methods for Determining Formaldehyde in Environmental Samples .............. 112 6-3. Ongoing Studies on Formaldehyde .................................................................................... 114 7-1. Regulations, Advisories, and Guidelines Applicable to Formaldehyde ............................. 117
Load more

Recommended publications
  • Nasal Airflow Measured by Rhinomanometry Correlates with Feno in Children with Asthma
    RESEARCH ARTICLE Nasal Airflow Measured by Rhinomanometry Correlates with FeNO in Children with Asthma I-Chen Chen1☯, Yu-Tsai Lin2☯, Jong-Hau Hsu1,3, Yi-Ching Liu1, Jiunn-Ren Wu1,3, Zen- Kong Dai1,3* 1 Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 3 Department of Pediatrics, School of Medicine, College of Medicine, a11111 Kaohsiung Medical University, Kaohsiung, Taiwan ☯ These authors contributed equally to this work. * [email protected] Abstract OPEN ACCESS Citation: Chen I-C, Lin Y-T, Hsu J-H, Liu Y-C, Wu Background J-R, Dai Z-K (2016) Nasal Airflow Measured by Rhinitis and asthma share similar immunopathological features. Rhinomanometry is an Rhinomanometry Correlates with FeNO in Children with Asthma. PLoS ONE 11(10): e0165440. important test used to assess nasal function and spirometry is an important tool used in doi:10.1371/journal.pone.0165440 asthmatic children. The degree to which the readouts of these tests are correlated has yet Editor: Stelios Loukides, National and Kapodistrian to be established. We sought to clarify the relationship between rhinomanometry measure- University of Athens, GREECE ments, fractional exhaled nitric oxide (FeNO), and spirometric measurements in asthmatic Received: September 3, 2016 children. Accepted: October 11, 2016 Methods Published: October 28, 2016 Patients' inclusion criteria: age between 5 and 18 years, history of asthma with nasal symp- Copyright: © 2016 Chen et al. This is an open toms, and no anatomical deformities. All participants underwent rhinomanometric evalua- access article distributed under the terms of the Creative Commons Attribution License, which tions and pulmonary function and FeNO tests.
    [Show full text]
  • Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy
    Medical Coverage Policy Effective Date ............................................. 7/10/2021 Next Review Date ....................................... 3/15/2022 Coverage Policy Number .................................. 0554 Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy Table of Contents Related Coverage Resources Overview .............................................................. 1 Balloon Sinus Ostial Dilation for Chronic Sinusitis and Coverage Policy ................................................... 2 Eustachian Tube Dilation General Background ............................................ 3 Drug-Eluting Devices for Use Following Endoscopic Medicare Coverage Determinations .................. 10 Sinus Surgery Coding/Billing Information .................................. 10 Rhinoplasty, Vestibular Stenosis Repair and Septoplasty References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence
    [Show full text]
  • Medical Policy Directory of Documents Policy Number: 411
    Medical Policy Directory of Documents Policy Number: 411 Q: How do I comment on the documents? A: You can email us at [email protected]. Q: How do I find out which documents have changed? A: New and updated documents are posted to the system every week. To find out what has changed see the Provider Focus newsletter. Drugs ∙ Treatments ∙ Devices and Equipment ∙ Surgeries ∙ Other Drugs Medical Technology Assessment Investigational (Non-Covered) Services List 400 Ampyra™ (dalfampridine) 246 Antihyperlipidemics: A Prescription Drug Therapy Guideline 013 ↳Prior Authorization/ Formulary Exception Form 434 Anti-Parkinsonism Drugs 054 Antisense Oligonucleotide Medications 027 Asthma and Chronic Obstructive Pulmonary Disease Medication Management 011 ↳Prior Authorization/ Formulary Exception Form 434 Benign Prostatic Hyperplasia (BPH) 040 Bisphosphonate, Oral 058 Botulinum Toxin Injections 006 B-Type Natriuretic Peptide 031 Anti-Migraine Policy 021 CNS Stimulants and Psychotherapeutic Agents 019 Compound Exclusion List for Pharmacy Medical Policy 579, Compounded Medications 705 Compound Inclusion List for Pharmacy Medical Policy 579, Compounded Medications 704 Compounded Medications 579 Cox II Inhibitor Drugs 002 Diabetes Step Therapy 041 Dificid (fidaxomicin) 700 Drug Management and Prior Authorization 251 ↳Prior Authorization/ Formulary Exception Form 434 Drugs for Cystic Fibrosis 408 Entresto Step Therapy 063 Erythropoietin, Recombinant Human; Epoetin Alpha (Epogen and Procrit); Darbepoetin Alpha 262 (Aranesp) Esketamine Nasal Spray (Spravato)
    [Show full text]
  • And Post-Pyriform Plasty Nasal Airflow
    Braz J Otorhinolaryngol. 2018;84(3):351---359 Brazilian Journal of OTORHINOLARYNGOLOGY www.bjorl.org ORIGINAL ARTICLE Evaluation of pre- and post-pyriform plasty nasal airflowଝ ∗ Oscimar Benedito Sofia , Ney P. Castro Neto, Fernando S. Katsutani, Edson I. Mitre, José E. Dolci Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil Received 29 November 2016; accepted 28 March 2017 Available online 6 May 2017 KEYWORDS Abstract Introduction: Nasal obstruction; Nasal obstruction is a frequent complaint in otorhinolaryngology outpatient clin- Rhinomanometry; ics, and nasal valve incompetence is the cause in most cases. Scientific publications describing Acoustic rhinometry surgical techniques on the upper and lower lateral cartilages to improve the nasal valve are also quite frequent. Relatively few authors currently describe surgical procedures in the piri- form aperture for nasal valve augmentation. We describe the surgical technique called pyriform plasty and evaluate its effectiveness subjectively through the NOSE questionnaire and objec- tively through the rhinomanometry evaluation. Objective: To compare pre- and post-pyriform plasty nasal airflow variations using rhinomanom- etry and the NOSE questionnaire. Methods: Eight patients submitted to pyriform surgery were studied. These patients were screened in the otorhinolaryngology outpatient clinic among those who complained of nasal obstruction, and who had a positive response to Cottle maneuver. They answered the NOSE questionnaire and were submitted to preoperative rhinomanometry. After 90 days, they were reassessed through the NOSE questionnaire and the postoperative rhinomanometry. The results of these two parameters were compared pre- and postoperatively. Results: Regarding the subjective measure, the NOSE questionnaire, seven patients reported improvement, of which two reported marked improvement, and one patient reported an unchanged obstructive condition.
    [Show full text]
  • The Potential of Computational Fluid Dynamics Simulations of Airflow in the Nasal Cavity
    Berger et al., J Neurobiol Physiol 2021; Journal of Neurobiology and Physiology 3(1):10-15. Short Communication The potential of computational fluid dynamics simulations of airflow in the nasal cavity Berger M1,2, Pillei M1,3, Freysinger W2* 1Department of Environmental, Process Abstract & Energy Engineering, MCI – The Entrepreneurial School, Austria Computational Fluid Dynamics (CFD) is a well-established and accepted tool for simulation and prediction of complex physical phenomena e.g., in combustion, aerodynamics or blood circulation. 2University Hospital of Recently CFD has entered the medical field due to the readily available high computational power of Otorhinolaryngology, Medical current graphics processing units, GPUs. Efficient numerical codes, commercial or open source, are University Innsbruck, Austria available now. Thus, a wide range of medical themes is available for CFD almost in real-time in the 3Department of Fluid Mechanics, medical environment now. Friedrich-Alexander University The available methods are on the point of reaching a usability status ready for everyday clinical use Erlangen-Nuremberg, Germany as a potential medical decision support system, provided adherence to the appropriate patient data *Author for correspondence: protection rules and proper certification as a medical device. Email: wolfgang.freysinger@i-med. ac.at This contribution outlines the current range of activities in our clinic in the field of Lattice-Boltzmann CFD based on CT and / or MR imagery and flashlights the following three areas: simulating the effect Received date: November 05, 2020 of nasal stents on breathing, predicting clinical Rhinomanometry and Rhinometry, and the numerical Accepted date: February 23, 2021 estimation of resection volumes for surgery to improve nasal breathing.
    [Show full text]
  • Alteraes Na Mucosa Nasal Provocadas Pela Presso Atmosfrica, Oxignio E
    ALTERAÇÕES NA MUCOSA NASAL PROVOCADAS PELA PRESSÃO ATMOSFÉRICA, OXIGÉNIO E OUTROS FACTORES PAULO SÉRGIO ALVES VERA-CRUZ PINTO Dissertação de doutoramento em Ciências Médicas 2009 PAULO SÉRGIO ALVES VERA-CRUZ PINTO ALTERAÇÕES NA MUCOSA NASAL PROVOCADAS PELA PRESSÃO ATMOSFÉRICA, OXIGÉNIO E OUTROS FACTORES Dissertação de candidatura ao grau de Doutor em Ciências Médicas, submetida ao Instituto de Ciências Biomédicas de Abel Salazar da Universidade do Porto. Orientador – Professor Doutor Carlos Zagalo, professor do Instituto de Ciências da Saúde Egas Moniz. Co-Orientador – Professor Doutor Artur Águas, professor catedrático do Instituto de Ciências Biomédicas de Abel Salazar da Universidade do Porto. Porto 2009 2 À Carla, ao Gonçalo e ao Bernardo 3 4 “Try and leave this world a little better than you found it and when your turn come to die, you can die happy in feeling that at any rate you have not wasted your time but have done your best.” Lord Robert Baden-Powell's Last Message to Scouts, 1941 5 6 ÍNDICE Preceitos legais ...................................................................................................................9 Agradecimentos.................................................................................................................10 INTRODUÇÃO...................................................................................................................12 1- Anatomia das Fossas Nasais no Humano ................................................................12 2 - Anatomia das Fossas Nasais no Rato .....................................................................14
    [Show full text]
  • Partitioning of Inhaled Ventilation Between the Nasal and Oral Routes During Sleep in Normal Subjects
    J Appl Physiol 94: 883–890, 2003. First published November 1, 2002; 10.1152/japplphysiol.00658.2002. Partitioning of inhaled ventilation between the nasal and oral routes during sleep in normal subjects MICHAEL F. FITZPATRICK, HELEN S. DRIVER, NEELA CHATHA, NHA VODUC, AND ALISON M. GIRARD Department of Medicine, Queen’s University, Kingston, Ontario, Canada K7L 3N6 Submitted 18 July 2002; accepted in final form 28 October 2002 Fitzpatrick, Michael F., Helen S. Driver, Neela the snore vibration, which can originate from the soft Chatha, Nha Voduc, and Alison M. Girard. Partitioning palate or from the tongue base (30), may vary during of inhaled ventilation between the nasal and oral routes the night (10). In patients with obstructive sleep apnea during sleep in normal subjects. J Appl Physiol 94: 883–890, (OSA), one study demonstrated a change in the pri- 2003. First published November 1, 2002; 10.1152/jappl- mary site of upper airway obstruction with sleep stage, physiol.00658.2002.—The oral and nasal contributions to from the velopharyngeal level in non-REM sleep to the inhaled ventilation were simultaneously quantified during sleep in 10 healthy subjects (5 men, 5 women) aged 43 Ϯ 5 yr, hypopharyngeal level during REM sleep (4). Ϫ1 Ϫ1 The advent of the nasal cannula pressure transducer with normal nasal resistance (mean 2.0 Ϯ 0.3 cmH2O⅐l ⅐s ) by use of a divided oral and nasal mask. Minute ventilation as the preferred device for airflow measurement during awake (5.9 Ϯ 0.3 l/min) was higher than that during sleep sleep, because of its higher sensitivity for detection of (5.2 Ϯ 0.3 l/min; P Ͻ 0.0001), but there was no significant airflow limitation (27), is also predicated on the as- difference in minute ventilation between different sleep sumption that airflow during sleep is primarily via the stages (P ϭ 0.44): stage 2 5.3 Ϯ 0.3, slow-wave 5.2 Ϯ 0.2, and nasal route, regardless of sleep stage.
    [Show full text]
  • Proceedings of the British Thoracic Society
    Thorax 1983;38:700-719 Thorax: first published as 10.1136/thx.38.9.700 on 1 September 1983. Downloaded from Proceedings of the British Thoracic Society The 1983 Summer Meeting of the British Thoracic Society was held on 27-29 June in the University of Cambridge BTS smoking withdrawal study: fators assodated with four there was continuing "active" disease at the time of giving up smoking death. The average follow-up in this supplementary series is six years and to date there has been only one simple IA CAMPBELL for BTS Research Committee In the British tumour (neurilemmoma). Thoracic Society's smoking withdrawal study 9-7% of 1550 patients successfully gave up smoking. Reasons for wanting to stop smoking, apart from improvement in Treatment of pneumothorax by simple aspiration health, were expense (30%), dislike of addiction (20%) and "dirty habit" (18%). Concern about weight gain was AAD HAMILTON, GJ ARCHER All the patients admitted to expressed by 41% of men and 59% of women. Men were Stepping Hill Hospital with an uncomplicated more successful than women and success in both sexes pneumothorax requiring treatment during the 12 months increased with age. Men with ischaemic heart disease did up to January 1983 were admitted to the study. These best (21% success). Married or single men were more patients, numbering 10, were treated by simple aspiration likely to give up smoking than divorced or separated men. of air using a plastic cannula used for intravenous insertion. Patients whose "most important other person" was a non- In seven patients the procedure was successful.
    [Show full text]
  • Upper and Lower Respiratory Disease, Edited by J
    UPPER AND LOWER R ESP1RAT0 RY DISEASE Edited by Jonathan Corren Allergy Research Foundation, Inc. Los Angeles, California, U.S.A. Alkis Togias Johns Hopkins Asthma and Allergy Center Baltimore, Maryland, U.S.A. Jean Bousquet Hdpital Arnaud de Villeneuve Montpellier, France MARCEL MARCELDEKKER, INC. NEWYORK RASEL DEKKER Although great care has been taken to provide accurate and current information, neither the author(s) nor the publisher, nor anyone else associated with this publica- tion, shall be liable for any loss, damage, or liability directly or indirectly caused or alleged to be caused by this book. The material contained herein is not intended to provide specific advice or recommendations for any specific situation. Trademark notice: Product or corporate names may be trademarks or registered trade- marks and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress. ISBN: 0-8247-0723-0 This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc., 270 Madison Avenue, New York, NY 10016, U.S.A. tel: 212-696-9000; fax: 212-685-4540 Distribution and Customer Service Marcel Dekker, Inc., Cimarron Road, Monticello, New York 12701, U.S.A. tel: 800-228-1160; fax: 845-796-1772 Eastern Hemisphere Distribution Marcel Dekker AG, Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-260-6300; fax: 41-61-260-6333 World Wide Web http://www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities.
    [Show full text]
  • Thieme: Ear, Nose, and Throat Diseases
    445 Subject Index Page numbers in italics denote figures and those in bold denote tables A adenomas, salivarygland 428 –430, anosmia 125,136 abscesses 429, 432 anotia 49, 49 brain see under brain pleomorphic see pleomorphic anterior rhinoscopy129 –131, 131 cervical soft tissue 388 adenoma antibiotic(s) epidural 188, 188 adhesive otitis 76, 76 aminoglycoside 95–96 nasal septal 199–200 aerosol inhalation 158 ototoxic 95–96 oral floor 256, 260, 260 aerotitis 87 resistance 440 orbital 186,187,187 age-related hearing loss 17 rhinosinusitis management 160 peritonsillar 270,270–272, 271 agnosia, acoustic 104 topical 144 retropharyngeal 273, 273 agranulocytosis 265 upper respiratory/digestive tract subdural 188,188–189 AIDS (acquired immune deficiency diseases 159 subperiosteal 66, 66, 186,187 syndrome) 251,251–252 antiseptics, topical 144 achalasia 362,371 aids, hearing 106, 106,107,107 antrostomy175, 176 cricopharyngeal 371–372 air conduction 28 anulus fibrosus 4, 5,69 acid burns airflow, nasal 126,126–127 aperiodic vibration 15, 15 esophageal 362,365–366 alae, nasal, anomalies 215, 217 aphasia 340–342, 341, 343 oral/pharyngeal 277–278 alkali burns aphthae 252 acinic cell tumors, salivary432 esophageal 362,365–366 articulation disorder 336 acoustic agnosia 104 oral/pharyngeal 277–278 arytenoidectomy, partial 305, 307 acoustic end organ see cochlea allergens, ear 54, 54 ataxia 20 acoustic neuroma 92,92,93, 94 allergic glossitis 256–257 atresia acoustic rhinomanometry136 allergic rhinitis 150–151, 151 choanal 211–212 acoustic trauma, acute 88 allergic
    [Show full text]
  • Omnibus Codes – Commercial Medical Policy
    UnitedHealthcare® Commercial Medical Policy Omnibus Codes Policy Number: 2021T0535III Effective Date: May 1, 2021 Instructions for Use Table of Contents Page Community Plan Policy Coverage Summary........................................................................... 1 • Omnibus Codes Coverage Rationale/Clinical Evidence .........................................12 Policy History/Revision Information........................................... 171 Instructions for Use ...................................................................... 174 Coverage Summary All CPT/HCPCS codes/services addressed in this policy are noted in the table below. Click the code link to be directed to the full coverage rationale and clinical evidence applicable to each of the listed procedures. CPT® is a registered trademark of the American Medical Association Code Description Conclusion 0042T Cerebral perfusion analysis using computed tomography with contrast Proven in certain administration, including post-processing of parametric maps with circumstances determination of cerebral blood flow, cerebral blood volume, and mean transit time 0061U Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], Unproven oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis 0100T Placement of a subconjunctival retinal prosthesis receiver and pulse Unproven generator, and implantation of intra-ocular retinal
    [Show full text]
  • Airway Abnormalities in Very Early Treated Infantile‐Onset Pompe
    Received: 12 July 2019 Revised: 8 December 2019 Accepted: 16 December 2019 DOI: 10.1002/ajmg.a.61481 ORIGINAL ARTICLE Airway abnormalities in very early treated infantile-onset Pompe disease: A large-scale survey by flexible bronchoscopy Chia-Feng Yang1,2 | Dau-Ming Niu1,2 | Shyh-Kuan Tai2,3 | Ting-Hao Wang1,2 | Hsiao-Ting Su4 | Ling-Yi Huang1 | Wen-Jue Soong1,2,5 1Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan Abstract 2School of Medicine, National Yang-Ming Early enzyme replacement therapy (ERT) improve long-term outcomes in patients University, Taipei, Taiwan with infantile-onset Pompe disease (IOPD). Our cohort of patients with IOPD at Tai- 3Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan pei Veterans General Hospital (TVGH) joined Taiwan Pompe newborn screening pro- 4Department of Audiology and Speech gram from 2008, testing more than one million newborns until 2018. By 2010, we Language Pathology, Mackay Medical College, had established rapid diagnostic strategies. Now, the average age of ERT initiation Taipei, Taiwan starts at an average age of <10 days-old, the earliest group in the world. However, 5Children's Hospital, China Medical University, Taichung, Taiwan they still presented some airway problems. We present a retrospective study focused on airway abnormalities in these patients along 8 years of observation. Fifteen Correspondence Wen-Jue Soong, Department of Pediatrics, patients with IOPD, who received very early treatment at a mean age of 8.94 Taipei Veterans General Hospital, No.201, Sec. ± 3.75 days, underwent flexible bronchoscopy (FB) for dynamic assessment of the 2, Shipai Rd., Beitou District, Taipei City, Taiwan 11217, China.
    [Show full text]